Chimeric antigen receptor modified T (CAR-T) cell therapy by targeting the CD19 antigen has made breakthroughs in the treatment of NHL at advanced stage, and showed the possibility of cure (15). This evidence concerns the gene CD19 and non-Hodgkin lymphoma.